Abstract
Activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum ß-lactamase (ESBL)-producing Klebsiella pneumoniae strain were studied in vitro and in vivo in septic mice using a high inoculum. Susceptibility to ciprofloxacin and levofloxacin was independent of the inoculum size. In killing curve studies, after 24 hours the initial 7.69 log 10 CFU / ml increased in the control to 9.34, while it was reduced to 4.83 by ciprofloxacin and to 4.25 by levofloxacin. Mice were infected with 10 7 CFU / g of K. pneumoniae intraperitoneally. Treatment started 2 hours later, when the mean blood bacterial counts were 7.33 log 10 CFU / ml, and lasted for 26 hours from the time of infection. Blood bacterial count was reduced from 7.33 log 10 CFU / ml to 4.08 log 10 CFU / ml by ciprofloxacin (20mg / kg / 6 hours), and to 3.60 log 10 CFU / ml by levofloxacin (50 mg / kg / 6 hours) 8 hours after the infection, which differed significantly from the infected untreated group. Ciprofloxacin and levofloxacin prolonged significantly the survival of mice compared with the infected untreated group (p < 0.001 for both groups). There were not significant differences either in the survival (p=1.0) or in the blood bacterial counts (p=0.216 after 8 hours) between ciprofloxacin and levofloxacin group. Based on these results both ciprofloxacin and levofloxacin could be alternative therapeutic agents for the infection caused by ESBL-producing Klebsiella strains.
Keywords: Ciprofloxacin and Levofloxacin, trimethoprim-sulfametoxazole, ESBL-producing strains, fluoroquinolons
Current Medicinal Chemistry
Title: In Vitro and In Vivo Activities of Ciprofloxacin and Levofloxacin against an SHV-5 Extended-Spectrum ß-Lactamase-Producing Klebsiella pneumoniae Strain
Volume: 9 Issue: 4
Author(s): Dora Szabo, Andras Mathe, Jozsef Lengyel, Piroska Anderlik, Laszlo Rokusz and Ferenc Rozgonyi
Affiliation:
Keywords: Ciprofloxacin and Levofloxacin, trimethoprim-sulfametoxazole, ESBL-producing strains, fluoroquinolons
Abstract: Activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum ß-lactamase (ESBL)-producing Klebsiella pneumoniae strain were studied in vitro and in vivo in septic mice using a high inoculum. Susceptibility to ciprofloxacin and levofloxacin was independent of the inoculum size. In killing curve studies, after 24 hours the initial 7.69 log 10 CFU / ml increased in the control to 9.34, while it was reduced to 4.83 by ciprofloxacin and to 4.25 by levofloxacin. Mice were infected with 10 7 CFU / g of K. pneumoniae intraperitoneally. Treatment started 2 hours later, when the mean blood bacterial counts were 7.33 log 10 CFU / ml, and lasted for 26 hours from the time of infection. Blood bacterial count was reduced from 7.33 log 10 CFU / ml to 4.08 log 10 CFU / ml by ciprofloxacin (20mg / kg / 6 hours), and to 3.60 log 10 CFU / ml by levofloxacin (50 mg / kg / 6 hours) 8 hours after the infection, which differed significantly from the infected untreated group. Ciprofloxacin and levofloxacin prolonged significantly the survival of mice compared with the infected untreated group (p < 0.001 for both groups). There were not significant differences either in the survival (p=1.0) or in the blood bacterial counts (p=0.216 after 8 hours) between ciprofloxacin and levofloxacin group. Based on these results both ciprofloxacin and levofloxacin could be alternative therapeutic agents for the infection caused by ESBL-producing Klebsiella strains.
Export Options
About this article
Cite this article as:
Szabo Dora, Mathe Andras, Lengyel Jozsef, Anderlik Piroska, Rokusz Laszlo and Rozgonyi Ferenc, In Vitro and In Vivo Activities of Ciprofloxacin and Levofloxacin against an SHV-5 Extended-Spectrum ß-Lactamase-Producing Klebsiella pneumoniae Strain, Current Medicinal Chemistry 2002; 9 (4) . https://dx.doi.org/10.2174/0929867023370923
DOI https://dx.doi.org/10.2174/0929867023370923 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements